Zoetis Inc. (ZTS) Given a $80.00 Price Target by Cowen and Company Analysts

Cowen and Company set a $80.00 price target on Zoetis Inc. (NYSE:ZTS) in a report published on Friday. The firm currently has a buy rating on the stock.

ZTS has been the subject of a number of other reports. Zacks Investment Research raised shares of Zoetis from a hold rating to a buy rating and set a $71.00 price objective for the company in a research note on Thursday, October 12th. Cantor Fitzgerald reissued a buy rating and issued a $75.00 price objective on shares of Zoetis in a research note on Wednesday, September 6th. BidaskClub cut shares of Zoetis from a hold rating to a sell rating in a research note on Friday, October 6th. Morgan Stanley lifted their price objective on shares of Zoetis from $61.00 to $70.00 and gave the stock an equal weight rating in a research note on Friday, November 3rd. Finally, The Goldman Sachs Group, Inc. reissued a neutral rating and issued a $62.00 price objective on shares of Zoetis in a research note on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have given a buy rating to the company. Zoetis presently has an average rating of Buy and an average price target of $67.65.

Shares of Zoetis (NYSE ZTS) traded up $0.38 during trading hours on Friday, hitting $70.79. 2,337,803 shares of the company’s stock were exchanged, compared to its average volume of 2,806,257. Zoetis has a 1-year low of $48.55 and a 1-year high of $71.12. The stock has a market cap of $34,310.00, a PE ratio of 32.06, a P/E/G ratio of 2.04 and a beta of 1.02. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.02. Zoetis had a net margin of 18.29% and a return on equity of 62.39%. The business had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period last year, the company posted $0.52 EPS. The business’s revenue was up 8.5% on a year-over-year basis. equities research analysts forecast that Zoetis will post 2.37 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This report was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://sportsperspectives.com/2017/11/18/zoetis-inc-zts-given-a-80-00-price-target-by-cowen-and-company-analysts.html.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Thursday, November 9th will be paid a dividend of $0.105 per share. The ex-dividend date of this dividend is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.59%. Zoetis’s dividend payout ratio is presently 22.11%.

Institutional investors have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. boosted its position in Zoetis by 16.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after buying an additional 230 shares during the period. Harfst & Associates Inc. boosted its position in Zoetis by 16.1% in the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after buying an additional 260 shares during the period. Almanack Investment Partners LLC. purchased a new stake in Zoetis in the 2nd quarter valued at about $119,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Zoetis by 251.9% in the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after buying an additional 1,360 shares during the period. Finally, Peddock Capital Advisors LLC purchased a new stake in Zoetis in the 2nd quarter valued at about $140,000. 92.44% of the stock is owned by institutional investors.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply